Clinical Trials | AdventHealth Research Institute

Showing 1 - 2 of 2 clinical trials matching your search

NCT03962543

A Phase 2b Trial of the MEK 1/2 Inhibitor (MEKi) PD-0325901 in Adult and Pediatric Patients with Neurofibromatosis Type 1 (NF1)-Associated Inoperable Plexiform Neurofibromas (PNs) that are Progressing or Causing Significant Morbidity

This study is currently enrolling.

Associated Conditions: Neurofibromatosis

Research Area: Pediatrics Research

Research Location: Orlando, Florida

This research is conducted to study an investigational drug referred to as PD-0325901 (also known as mirdametinib) that has not been approved by the US Food and Drug Administration (FDA) or any other...
NCT03871257

A Phase 3 Randomized Study of Selumetinib (IND# 77782) versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)

This study is not currently enrolling.

Associated Conditions: Brain Cancer

Research Area: Pediatrics Research

Research Location: Orlando, Florida

The overall goals of this study are to see if selumetinib works just as well as the standard treatment of carboplatin/vincristine (CV) for subjects with NF1-associated LGG, and to see if selumetinib...